Premium
siRNA‐Mediated Down‐regulation of Vascular Endothelial Growth Factor in MCF‐7 cells
Author(s) -
Patel Khyati Rohit,
Bhatt Vrushank D,
Boggeti Renuka,
Ratna Warren N
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1038.16
Subject(s) - angiogenesis , vascular endothelial growth factor , small interfering rna , western blot , microbiology and biotechnology , transfection , cancer research , northern blot , rna interference , vascular endothelial growth factor a , blot , mcf 7 , biology , messenger rna , cell culture , chemistry , rna , cancer cell , cancer , gene , vegf receptors , biochemistry , genetics , human breast
Vascular endothelial growth factor (VEGF) promotes angiogenesis and vascularization. Inhibition of angiogenesis results in tumor regression. VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. Deregulated VEGF expression contributes to angiogenesis and tumor growth and the etiology of several other diseases that are characterized by abnormal angiogenesis. VEGF family of genes include VEGF‐A, VEGF‐B, VEGF‐C and VEGF‐D. To investigate targeted degradation of VEGF mRNA using short interference RNA (siRNA) as a means to inhibit VEGF expression, MCF‐7 human breast cancer cells were transfected with phosphothioester siRNAs designed to degrade VEGF mRNAs. RNA was extracted by NP‐40 lysis method and analyzed by Reverse Transcription‐Polymerase Chain Reaction (RT‐PCR) and Northern blotting. Western blot analysis was performed on whole cell lysates. RT‐PCR and Northern blot analysis showed siRNA‐mediated degradation of VEGF mRNA. Western blot analysis showed a corresponding decrease in the expression of VEGF. The above results indicate the potential use of siRNA for the down regulation of VEGF expression and consequently cause tumor regression. This work was supported by science research funds from Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY.